Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
S-606001 as a Monotherapy in Adult Patients With Late-onset Pompe Disease
NCT07787650Phase 1Not yet recruiting
- Sponsor
- Shionogi & Co., Ltd.
- Start
- Sep 2026
- Primary completion
- Oct 2028
01
Overview
Phase 1, open-label, single-arm trial of S-606001 in Pompe disease, sponsored by Shionogi & Co., Ltd. Primary endpoint: Number of Participants with Treatment-emergent Adverse Events at Week 49. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
S-606001
03
Conditions
Pompe disease
Beyond the preview
Go deeper on NCT07787650.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07787650.